Search
for
Sort by
Research 91–120 of 290
- COVID-19 and andrology: Recommendations of the French-speaking society of andrology (Société d’Andrologie de langue Française SALF)
- Androgens in SARS-CoV-2 Coronavirus Infections
- Evaluation of COVID-19 risk in patients on systemic retinoid therapy
- Untangling the hairy issue of iron deficiency: Making progress
- Post COVID Alopecia in the Indian Subcontinent - A Harbinger of Disease Severity
- The role of hair follicles and Edar signalling in cutaneous wound healing
- Diet and hair loss: effects of nutrient deficiency and supplement use
- Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium
- Genome Array on Differentially Expressed Genes of Skin Tissue in Cashmere Goat at Early Anagen of Cashmere Growth Cycle Using DNA Microarray
- Iron deficiency and diffuse nonscarring scalp alopecia in women: More pieces to the puzzle
- Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
- Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis
- Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia
- Free Testosterone Levels in Patients with Covid-19 and its Association with Disease Severity
- Androgenetic alopecia in women and men is not related to COVID‐19 infection severity: a prospective cohort study of hospitalized COVID‐19 patients
- Identification of SLC40A1, LCN2, CREB5, and SLC7A11 as ferroptosis-related biomarkers in alopecia areata through machine learning
- Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
- Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride
- The 100 most cited articles in androgenetic alopecia: A bibliometric analysis
- Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
- SARS-CoV-2 vaccination in androgen sensitive phenotypes – A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients
- MAIT Cells in COVID-19: Heroes, Villains, or Both?
- Association of androgenetic alopecia with a more severe form of COVID-19 infection
- Testosterone in COVID-19: An Adversary Bane or Comrade Boon
- COVID-19: The question of genetic diversity and therapeutic intervention approaches
- Male sex hormones, aging, and inflammation
- SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism